The New Wave of Peptide Drugs for Fatty Liver Disease: What's Working and What's Next
GLP-1 drugs, dual/triple agonists, and other peptide-based therapies are showing strong results in treating MASH (fatty liver disease), with multiple agents resolving liver inflammation and improving scarring in clinical trials.
Quick Facts
What This Study Found
Multiple peptide-based therapies are showing substantial promise for treating MASH (metabolic dysfunction-associated steatohepatitis), the progressive form of fatty liver disease. GLP-1 agonists (semaglutide), dual agonists (tirzepatide, survodutide), and triple agonists are among the most advanced candidates. Recent trials demonstrate these drugs can resolve liver inflammation and improve fibrosis — the two key histological endpoints.
Other promising approaches include PPAR agonists (lanifibranor), FGF21 analogs (pegozafermin), THR-β agonists (resmetirom, the first FDA-approved MASH drug), and fatty acid synthase inhibitors. The field is moving toward combination therapies and precision medicine approaches using genetic variants like PNPLA3 to guide treatment selection.
Key Numbers
Review covering semaglutide, tirzepatide, survodutide, lanifibranor, pegozafermin, resmetirom · MASH is leading cause of chronic liver disease · driven by obesity + T2D
How They Did This
Comprehensive narrative review published in the Journal of Clinical Investigation. The authors synthesize evidence from recent clinical trials of MASH therapeutics, regulatory developments, biomarker research, and emerging precision medicine approaches. The review covers drugs from Phase II through FDA approval.
Why This Research Matters
MASH is now a leading cause of chronic liver disease globally, driven by the obesity and diabetes epidemics. Until recently there were no approved drugs for it. The emergence of incretin-based peptide therapies — many of them already approved for diabetes and obesity — represents a potential paradigm shift. These drugs could simultaneously treat patients' metabolic disease and their liver disease.
The Bigger Picture
MASH therapeutics is one of the hottest areas in drug development, with billions of dollars at stake. The convergence of GLP-1 drugs (already blockbusters for obesity), liver-targeted therapies, and precision medicine is creating an entirely new treatment paradigm. This review captures a pivotal moment: the transition from having no MASH drugs to having multiple promising candidates, many of them peptide-based, that address the metabolic root causes of the disease.
What This Study Doesn't Tell Us
As a review, this presents no new data. The field is moving rapidly, so some information may become outdated quickly. The review focuses on pharmacological approaches and gives less attention to lifestyle interventions. Many of the promising agents discussed are still in clinical trials and may not succeed.
Questions This Raises
- ?Will combination therapies (e.g., GLP-1 agonist plus a PPAR agonist) outperform single agents for MASH?
- ?How long do patients need to stay on these drugs to maintain liver improvements, and what happens when they stop?
- ?Can genetic profiling (like PNPLA3 variants) reliably predict which patients will respond best to which therapy?
Trust & Context
- Key Stat:
- MASH is now a leading cause of liver disease Multiple peptide-based therapies — including semaglutide, tirzepatide, and survodutide — are demonstrating the ability to resolve inflammation and improve fibrosis in clinical trials
- Evidence Grade:
- This is a review from a top-tier journal (Journal of Clinical Investigation) authored by leading MASH researchers. It synthesizes evidence from multiple Phase II/III trials and an FDA-approved drug. While it presents no new data, the quality of evidence reviewed is high.
- Study Age:
- Published in 2025. This is a very current review capturing the rapidly evolving MASH therapeutic landscape. Given the pace of drug development in this space, some specific trial results may have been updated since publication.
- Original Title:
- Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.
- Published In:
- The Journal of clinical investigation, 135(13) (2025)
- Authors:
- Newsome, Philip N(4), Loomba, Rohit(5)
- Database ID:
- RPEP-12765
Evidence Hierarchy
Frequently Asked Questions
What is MASH and why is it so dangerous?
MASH (metabolic dysfunction-associated steatohepatitis) is the inflammatory form of fatty liver disease. Unlike simple fatty liver, MASH causes progressive liver damage that can lead to cirrhosis, liver cancer, and liver failure. It's driven by obesity and type 2 diabetes and is now one of the leading causes of liver disease worldwide.
Can GLP-1 drugs like semaglutide treat fatty liver disease?
Clinical trials show semaglutide and related drugs (tirzepatide, survodutide) can resolve liver inflammation and improve fibrosis in MASH patients. While not all are formally approved for MASH yet, the evidence is strong enough that many doctors are already considering these drugs for patients who have both obesity/diabetes and fatty liver disease.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12765APA
Newsome, Philip N; Loomba, Rohit. (2025). Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.. The Journal of clinical investigation, 135(13). https://doi.org/10.1172/JCI186425
MLA
Newsome, Philip N, et al. "Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.." The Journal of clinical investigation, 2025. https://doi.org/10.1172/JCI186425
RethinkPeptides
RethinkPeptides Research Database. "Therapeutic horizons in metabolic dysfunction-associated ste..." RPEP-12765. Retrieved from https://rethinkpeptides.com/research/newsome-2025-therapeutic-horizons-in-metabolic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.